Alcon AG banner

EV/GP

6.7
Current
20%
Cheaper
vs 3-y average of 8.4

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
6.7
=
Enterprise Value
CHf31.8B
/
Gross Profit
$5.9B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
6.7
=
Enterprise Value
CHf31.8B
/
Gross Profit
$5.9B

Valuation Scenarios

Alcon AG is trading below its 3-year average

If EV/GP returns to its 3-Year Average (8.4), the stock would be worth CHf74.3 (25% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-27%
Maximum Upside
+28%
Average Upside
3%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 6.7 CHf59.48
0%
3-Year Average 8.4 CHf74.3
+25%
5-Year Average 8.6 CHf75.92
+28%
Industry Average 5.9 CHf52.25
-12%
Country Average 4.9 CHf43.28
-27%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CH
Alcon AG
SIX:ALC
29B CHF 6.7 37.1
JP
Hoya Corp
TSE:7741
9.9T JPY 11.8 39.6
US
Medline Inc
NASDAQ:MDLN
58.1B USD 0 0
DK
Coloplast A/S
CSE:COLO B
91B DKK 5.9 23.2
US
Align Technology Inc
NASDAQ:ALGN
12.7B USD 4.2 30.8
UK
ConvaTec Group PLC
LSE:CTEC
4.2B GBP 5.1 32.2
JP
Asahi Intecc Co Ltd
TSE:7747
905.8B JPY 9.5 51.2
CA
Bausch + Lomb Corp
NYSE:BLCO
5.6B USD 3.3 -15.4
KR
HLB Inc
KOSDAQ:028300
8.3T KRW 301.3 -37.8
CN
Intco Medical Technology Co Ltd
SZSE:300677
37.5B CNY 13.9 22
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.4B USD 6 23.1
P/E Multiple
Earnings Growth PEG
CH
Alcon AG
SIX:ALC
Average P/E: 32.4
37.1
32%
1.2
JP
Hoya Corp
TSE:7741
39.6
15%
2.6
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
DK
Coloplast A/S
CSE:COLO B
23.2
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
30.8
34%
0.9
UK
ConvaTec Group PLC
LSE:CTEC
32.2
41%
0.8
JP
A
Asahi Intecc Co Ltd
TSE:7747
51.2
40%
1.3
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.4 N/A N/A
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -37.8 N/A N/A
CN
Intco Medical Technology Co Ltd
SZSE:300677
22
12%
1.8
US
Lantheus Holdings Inc
NASDAQ:LNTH
23.1
30%
0.8

Market Distribution

In line with most companies in Switzerland
Percentile
60th
Based on 878 companies
60th percentile
6.7
Low
0 — 2.5
Typical Range
2.5 — 8.3
High
8.3 —
Distribution Statistics
Switzerland
Min 0
30th Percentile 2.5
Median 4.9
70th Percentile 8.3
Max 378.3

Alcon AG
Glance View

Alcon AG, headquartered in Geneva, Switzerland, emerges as a global leader in eye care, having spun off from Novartis in 2019 to operate independently. The company traces its roots back to a small pharmacy established in Fort Worth, Texas, in 1945, gradually expanding under the strategic vision of its founders. Today, Alcon stands at the intersection of innovation and necessity, catering to a world increasingly aware of eye health. The firm specializes in two main sectors: Surgical and Vision Care. In the Surgical division, Alcon offers advanced technologies and devices for ophthalmic surgery, encompassing cataract, retinal, and refractive procedures. Through these innovations, Alcon not only enhances patient outcomes but also streamlines operations for eye care professionals, carving out a significant market share in surgical solutions. Meanwhile, the Vision Care segment thrives by addressing the burgeoning demand for contact lenses and ocular health products. Alcon’s portfolio features daily disposable and reusable lenses, supported by innovative technologies that prioritize comfort and clarity of vision. Additionally, the company provides comprehensive eye care products, including lens care solutions, which enhance user satisfaction and ensure sustained demand. Alcon’s revenue model hinges on its ability to deliver cutting-edge products that meet the evolving needs of consumers and professionals alike. Through strategic investments in research and development and a strong distribution network, Alcon perpetually reinforces its market presence, securing its position as a formidable player in the eye care industry.

ALC Intrinsic Value
59.96 CHF
Undervaluation 1%
Intrinsic Value
Price CHf59.48
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett